glp 1 loss of muscle mass GLP-1 and Loss: Semaglutide, Tirzepatide & Lean Do GLP-1 medications really cause

The CYP3A biomarker 4-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

The KaiNETIC global Phase 3 program will ultimately determine whether ribupatide can match tirzepatide's efficacy in large, diverse populations with long-duration follow-up

Use point-of-care gastric ultrasound when feasible to assess for retained gastric contents

Men often carry weight differently than women, with more visceral fat around the abdomen, which can be more difficult to lose through diet and exercise alone

The expected benefits on heart disease, stroke and other cardiovascular and most kidney diseases are clearly seen